From Name:
From Email:
To Name:
To Email:

Optional Message:

Apixaban: An oral anticoagulant

from Pharmacy Times

Apixaban (Eliquis) was recently approved by the FDA as an oral anticoagulant (a direct inhibitor of factor Xa) to reduce the risk of embolism in patients with atrial fibrillation.1 As a potential alternative to warfarin, apixaban joins rivaroxaban (Xarelto; also a factor Xa inhibitor) and dabigatran (Pradaxa; a factor IIa inhibitor). Apixaban is partially metabolized by cytochrome P450 enzymes and is a substrate for efflux transporters. It is also eliminated by the kidneys, and reduced renal function results in some drug accumulation; dose reductions are suggested in elderly patients with renal dysfunction. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063